Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
7. The key ingredient for medtech innovation
SmartCells founder Todd Zion says getting a life science company from concept to commercialization depends on 1 key ingredient: A safe place for a good idea, like MIT’s pioneering Venture Mentoring Service.
6. Med-tech trends: The most talked about device makers in November 2012
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
5. FDA panel decision means Abiomed will need new PMA for Impella pump
An FDA advisory panel’s decision to maintain Class III status on certain cardiovascular assistance devices means Abiomed and other device makers must re-apply for FDA approval.
4. Court rules that convicted salesman’s off-label marketing is protected as free speech
A New York appeals court’s decision to reverse a conviction against a drug salesman accused of off-label promotion may have significant implications for the way the FDA regulates device and drug marketing.
How optimistic are you that medical device tax will be repealed? Take our survey.
3. IRS shows (some) mercy to medical device companies
The IRS will waive penalties for the first 3 quarters of 2013 for medical device companies who do not make semi-monthly payments on time due to "reasonable cause."
2. Medical device tax winners and losers
Medical device legal analyst Kristian Werling breaks down the newly released IRS medical device tax codes – who’s relieved, who’s wary and what happens now?
1. IRS makes levy a reality with final guidance documents
The 2.3% medical device excise tax takes another step closer to reality with the release of guidance documents by the IRS.
